SCHEMBL3405663

SCHEMBL3405663

Oc1cc(F)c(Br)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.46
HSD17B10 Q99714 4/20 0.46
HPGD P15428 2/20 0.46
KDM1A O60341 4/20 0.44
KDM1B Q8NB78 3/20 0.44
CYP3A4 P08684 2/20 0.36
ALDH1A1 P00352 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ADRA1A P35348 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
HSP90AA1 P07900 1/20 0.32
HSD17B1 P14061 1/20 0.32
HSD17B2 P37059 1/20 0.32
KCNH2 Q12809 2/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7160402 0.91 TSHR (0.46) TSHRHSD17B10HPGDKDM1AKDM1B
SCHEMBL5271664 0.81 KDM1A (0.36) TSHRHSD17B10HPGDKDM1AKDM1B
SCHEMBL30826229 0.79 KDM1A (0.50) KDM1AKDM1BALDH1A1TDP1NPC1
SCHEMBL1479085 0.79 KDM1A (0.50) KDM1AKDM1BALDH1A1TDP1NPC1
SCHEMBL18893969 0.79 HSD17B10 (0.55) TSHRHSD17B10HPGDCYP3A4ALDH1A1
SCHEMBL1697562 0.79 ALOX15 (0.38) TSHRHSD17B10KDM1AKDM1BCYP3A4
SCHEMBL30687171 0.79 ALOX15 (0.38) TSHRHSD17B10KDM1AKDM1BCYP3A4
SCHEMBL8640677 0.77 TSHR (0.52) TSHRHSD17B10HPGDCYP3A4ALDH1A1
SCHEMBL305189 0.77 TSHR (0.60) TSHRHSD17B10HPGDCYP3A4ALDH1A1
SCHEMBL29720512 0.77 TSHR (0.60) TSHRHSD17B10HPGDCYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 US disclosed
EP-4626860-A1 FUSED PYRROLYL-SULFONAMIDE COMPOUNDS ReWind Therapeutics NV (BE) 2025-10-08 EP disclosed
WO-2025049820-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
WO-2024115733-A1 FUSED PYRROLYL-SULFONAMIDE COMPOUNDS REWIND THERAPEUTICS NV (BE) 2024-06-06 WO disclosed
WO-2014106606-A1 NOVE PHENYL/PYRIDINE SERIES SUBSTITUED BY HYDROXYETHYLAMINO FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2014-07-10 WO disclosed
EP-2231595-B1 PHENYL ACETIC ACID DERIVATIVES AS INFLAMMATION MODULATORS AMGEN INC (US) 2014-04-23 EP disclosed
US-8183293-B2 Phenyl acetic acid derivatives AMGEN INC. (US) 2012-05-22 US disclosed
US-8183293-B2 Phenyl acetic acid derivatives AMGEN INC. (US) 2012-05-22 US disclosed
US-8183293-B2 Phenyl acetic acid derivatives AMGEN INC. (US) 2012-05-22 US disclosed
US-7872018-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON, INC. (US) 2011-01-18 US disclosed
US-20090275659-A1 Phenyl acetic acid derivatives as inflammation modulators AMGEN INC. (US) 2009-11-05 US disclosed
EP-2094701-A2 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2009-09-02 EP disclosed
WO-2009085177-A1 PHENYL ACETIC ACID DERIVATIVES AS INFLAMMATION MODULATORS AMGEN INC. (US) 2009-07-09 WO disclosed
WO-2009085177-A1 PHENYL ACETIC ACID DERIVATIVES AS INFLAMMATION MODULATORS AMGEN INC. (US) 2009-07-09 WO disclosed
US-20080221148-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC 2008-09-11 US disclosed
US-20080221148-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC 2008-09-11 US disclosed
US-20080221148-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC 2008-09-11 US disclosed
WO-2008080001-A2 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2008-07-03 WO disclosed
WO-2008080015-A2 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2008-07-03 WO disclosed
WO-2008080015-A2 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF STAT6, NCOR2, NCOR1 TSHR 70/4885HSD17B10 1507/4885HPGD 2098/4885
US-20080221148-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 TSHR 3443/4885HSD17B10 2754/4885HPGD 2589/4885
US-20090275659-A1 Phenyl acetic acid derivatives as inflammation modulators NFKBIA, HCAR2, NFATC1 TSHR 4792/4885HSD17B10 1001/4885HPGD 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.